RIPK1 binds ponatinib

Stable Identifier
R-HSA-9679839
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

TNF-alpha signaling leads to the assembly of a large receptor-bound signaling complex, which includes multiple adaptors (TRADD, TRAF2, and RIPK1), and E3 ubiquitin ligases (cIAP1/2, LUBAC complex). RIPK1 thus plays a critical role in mediating both normal and pathological responses downstream of TNFR1 and RIPK1 inhibitors, including ponatrinib, have progressed successfully passed human phase I clinical studies (Degterev et al. 2020, Najjar et al. 2015).

Literature References
PubMed ID Title Journal Year
31048504 Targeting RIPK1 for the treatment of human diseases

Degterev, A, Ofengeim, D, Yuan, J

Proc. Natl. Acad. Sci. U.S.A. 2019
25801024 Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1

Najjar, M, Suebsuwong, C, Ray, SS, Thapa, RJ, Maki, JL, Nogusa, S, Shah, S, Saleh, D, Gough, PJ, Bertin, J, Yuan, J, Balachandran, S, Cuny, GD, Degterev, A

Cell Rep 2015
Participants
Participates
Authored
Reviewed
Created
Cite Us!